Trending >

HEXO is a natural fit for a Fortune 500 partner, AltaCorp Capital says

HEXO Corp

Canadian cannabis company HEXO (HEXO Stock Quote, Chart TSX:HEXO) gets the nod from AltaCorp Capital’s David Kideckel, who launched coverage of the stock last Friday with an “Outperform” rating and one-year target price of $10.50.

Kideckel says HEXO’s focus on strategic partnerships combined with management’s proven ability to execute make for a solid future for the Gatineau, Quebec, licensed producer.

“As the market dynamics of the cannabis industry continue to evolve towards a focus on derivative products, including consumer packaged goods products and pharmaceuticals, we believe that HEXO’s business model, prioritizing operational scalability, product innovation and brand leadership, will ultimately position them as a trusted partner to Fortune 500 companies. The Company’s trend-setting partnership with Molson Coors is a major step in HEXO’s quest towards enhanced market leadership,” writes Kideckel.

The analyst points to HEXO already-solid distribution in Canada where HEXO, with the completion of its Newstrike acquisition, will have distribution agreements across nine provinces, including the industry-leading contract with Quebec. In total, management is guiding for $400.0 million in net revenue for 2020.

“HEXO operating facilities are strategically located allowing the Company to exploit a range of low- cost drivers. In Q2/19, HEXO reported impressive adj. gross margins at 52 per cent compared to an average of 43 per cent versus other mid-to-large-cap Canadian cannabis peers,” he says.

The analyst thinks HEXO will generate fiscal 2019 revenue and Adjusted EBITDA of $62.6 million and negative $34.1 million, respectively, and fiscal 2020 revenue and Adjusted EBITDA of $355.6 million and $69.8 million, respectively.

Kideckel’s valuation implies a forward multiple of 36.3x, 19.7x and 13.3x on his fiscal 2020, 2021 and 2022 Adjusted EBITDA estimates, while his $10.50 target implies a return of 19.9 per cent at the time of publication.

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook

Comment

Leave a Reply

Your email address will not be published. Required fields are marked *